The financing will support the company as it works to expand its diagnostic products for non-invasive early detection and monitoring of cancers.
Denmark-based Arcedi would like to commercialize its technology through a major diagnostic company.
The selective whole-genome amplification approach was successfully adapted to Plasmodium vivax, a parasite that is notoriously difficult to culture.
Following a recent acquisition in the proteomics space and several distribution deals, Sygnis has developed its first liquid biopsy product to be launched later this year.
Tataa will distribute the single-cell whole-genome amplification products in Sweden, Norway, Germany, Austria, Slovakia, and the Czech Republic.
The deal gives Australian distributor GeneWorks rights to promote, market, and sell all current and future products in Sygnis' portfolio.
The wholly-owned subsidiary, XCR Dx, will make a portable handheld instrument to use assays built on Fluoresentric's proprietary DNA amplification chemistry.
D-Mark will market and sell Sygnis' TruePrime Single Cell WGA kit, which eliminates the need for synthetic random primers.
NEW YORK (GenomeWeb) – Meridian Bioscience today announced that Health Canada has approved for marketing Meridian's molecular assays for Mycoplasma pneumonia and Bordetella pertussis on the company's illumigene platform.
NEW YORK (GenomeWeb News) – Meridian Bioscience today announced the US Food and Drug Administration cleared its molecular diagnostic test for Mycoplasma pneumonia.
The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.
A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.
Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.
In Science this week: analysis of DNA from ancient North Africans, and more.